TOP TEN perturbations for 39077_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39077_at
Selected probe(set): 227963_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39077_at (227963_at) across 6674 perturbations tested by GENEVESTIGATOR:

H14 BJI / H14.s3

Relative Expression (log2-ratio):5.6449423
Number of Samples:2 / 2
Experimental H14 BJI
Human embryonic stem cells H14 BJI with abnormal karyotype, including a homogenous staining region (48,XY,+12,+der(17)del(17)(p12p13.3)hsr(17)(p11.2)). Synonyms:H14 BJI; H14BJ1; H14.BJ1 Parental cell line:: WA14 Cellosaurus code:
Control H14.s3
Human embryonic stem cells H14.s3 with normal male karyotype. Parental cell line:: WA14

CAR T cell study 4 (PSCA-28t28Z; post-infusion) / CAR T cell study 4 (PSCA-28t28Z; pre-infusion)

Relative Expression (log2-ratio):-3.6624813
Number of Samples:3 / 3
Experimental CAR T cell study 4 (PSCA-28t28Z; post-infusion)
CD8+ T cells transduced with PSCA-28t28Z (second generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-28t28Z. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control CAR T cell study 4 (PSCA-28t28Z; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):3.5549555
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

CAR T cell study 4 (PSCA-8t28BBZ; post-infusion) / CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion)

Relative Expression (log2-ratio):-3.363861
Number of Samples:3 / 3
Experimental CAR T cell study 4 (PSCA-8t28BBZ; post-infusion)
CD8+ T cells transduced with PSCA-8t28BBZ (third generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-8t28BBZ. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-8t28BBZ (third generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

PBDE study 1 (2-OH-BDE85) / vehicle (DMSO) treated H295R cell sample

Relative Expression (log2-ratio):3.2679758
Number of Samples:3 / 3
Experimental PBDE study 1 (2-OH-BDE85)
H295R adrenocortical carcinoma cells treated for 24 hours with 10µM of a hydroxylated form of the brominated flame retardant 2-OH-BDE85 dissolved in 0.1% dimethyl sulfoxide (DMSO). ATC code:---
Control vehicle (DMSO) treated H295R cell sample
H295R adrenocortical carcinoma cells grown for 24 hours with 0.1% dimethyl sulfoxide (DMSO).

glioma study 17 (astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):3.2429771
Number of Samples:3 / 3
Experimental glioma study 17 (astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from low grade astrocytoma (grade II). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 36 ± 7 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

PBDE study 1 (2-OH-BDE47) / vehicle (DMSO) treated H295R cell sample

Relative Expression (log2-ratio):3.1413507
Number of Samples:3 / 3
Experimental PBDE study 1 (2-OH-BDE47)
H295R adrenocortical carcinoma cells treated for 24 hours with 10µM of a hydroxylated form of the brominated flame retardant 2-OH-BDE47 dissolved in 0.1% dimethyl sulfoxide (DMSO). ATC code:---
Control vehicle (DMSO) treated H295R cell sample
H295R adrenocortical carcinoma cells grown for 24 hours with 0.1% dimethyl sulfoxide (DMSO).

PIK-75 study 1 / vehicle (solvent) treated H69 cell sample

Relative Expression (log2-ratio):3.1054106
Number of Samples:3 / 3
Experimental PIK-75 study 1
H69 cells (small cell lung cancer) treated with PIK-75, a small molecule affecting PIK3CA (Phodphoinositide-3-kinase catalytic subunit alpha: p110-α) ATC code:---
Control vehicle (solvent) treated H69 cell sample
H69 cells (small cell lung cancer) grown in growth medium with solvent.

CAR T cell study 4 (GFP; post-infusion) / CAR T cell study 4 (GFP; pre-infusion)

Relative Expression (log2-ratio):-3.0524654
Number of Samples:3 / 3
Experimental CAR T cell study 4 (GFP; post-infusion)
CD8+ T cells transduced with GFP and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing GFP (control group). Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control CAR T cell study 4 (GFP; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express GFP. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

TGX-221 study 2 / PIK-75 study 1

Relative Expression (log2-ratio):-2.884962
Number of Samples:3 / 3
Experimental TGX-221 study 2
H69 cells (small cell lung cancer) treated with TGX-221, a small molecule affecting PIK3CB (Phodphoinositide-3-kinase catalytic subunit beta: p110-ß) ATC code:---
Control PIK-75 study 1
H69 cells (small cell lung cancer) treated with PIK-75, a small molecule affecting PIK3CA (Phodphoinositide-3-kinase catalytic subunit alpha: p110-α) ATC code:---